Category: Insights

Newer gene immunotherapies, such as CAR T-cell therapies, can provide life-saving treatments for patients with rare blood disorders. Associate Partner Dennis Fournogerakis describes in PM360 Magazine how manufacturers can overcome commercial challenges at launch and beyond to help treatment centers offer these cutting-edge therapies to patients who need it most.

Life sciences companies must anticipate various scenarios and successfully navigate any turbulence as they launch new products during a pandemic. Vice President Janardhan Vellore describes in PM360 Magazine how commercial teams can challenge the status quo to rewrite the product launch playbook and position products for long-term success.

Orphan drugs are different than mass-market therapies — and so is their commercial strategy. Orphan drug manufacturers should engage patients throughout research, development and commercialization — and hire specialized sales forces market the therapy to the most relevant physicians. Associate Partner Dan Schulman describes in Med Ad News the steps orphan drug manufacturers can take to ensure their life-saving treatments reach patients as quickly as possible.

The coronavirus presents several challenges for life sciences manufacturers – and how they respond will define them for years to come. Partner Steve Trokenheim and Associate Partner Dan Schulman describe in Pharmaceutical Executive how a measured approach to commercial operations can help navigate uncertainty and set up companies for long-term success.

An orphan drug manufacturer should follow the patient journey to account for various scenarios in the product’s forecast — from delays in therapy starts to patient compliance and retention. Associate Partner Rob Lien and Manager Esin Izat describe in Pharmaceutical Commerce how detailed analysis and marketing research can help life sciences companies overcome these challenges and contribute to commercial success.

A life sciences company’s sales forecast has downstream implications for many aspects of commercial operations, from targeting to incentive compensation. Partner Patrick Lezark describes in Med Ad News the importance of an accurate forecast to position the field sales force for success.

A life sciences company needs to rely on more than historical prescription volume to ensure product success in today’s hypercompetitive marketplace. Partner Dan Wetherill and Vice President Janardhan Vellore describe in Pharmaceutical Executive how life sciences companies can proactively increase the breadth and depth of prescriptions to propel brand performance.